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Madam, 
Whole-genome sequencing (WGS) and resistance gene annota- 
tion (RGA) has increasingly evolved as a routine method for molec- 
ular typing of clinical bacterial isolates in the diagnostic microbi- 
ology laboratory. WGS has proven particularly useful in outbreak 
detection and epidemiological surveillance and holds promise for 
in silico antimicrobial susceptibility testing (AST). However, a re- 
view by the European Committee on Antimicrobial Susceptibility 
Testing (EUCAST) has highlighted the need for additional evidence 
in support of WGS-inferred AST to guide clinical decision-making 
[1] . 
To unfold the full AST potential of WGS and RGA, a robust as- 
sociation between resistance genes and their effect on the pheno- 
type needs to be established, taking into account an ever-evolving 
complexity of circulating gene variants. To underscore the signifi- 
cance, we studied the clinical prevalence and phenotypic diversity 
of the AAC(3) family of aminoglycoside acetyltransferases, a family 
of resistance genes conferring resistance to aminoglycoside antibi- 
otics [ 2 , 3 ]. Despite considerable genetic diversity of aac(3) genes 
and 11 subtypes of AAC(3) enzymes previously described, our find- 
ings suggest a simplified scheme of four distinct clades, each with 
its own distinctive phenotype. 
We analysed the resistance gene annotations of 239 772 human 
bacterial isolates deposited in the NCBI National Database of An- 
tibiotic Resistant Organisms (NDARO) [4] to identify all genomes 
that code for at least one aac(3) gene. Subtype aac(3)-I was found 
to be the predominant aac(3) gene in Pseudomonas aeruginosa and 
Acinetobacter baumannii isolates, whereas aac(3)-II was the pre- 
dominant subtype in Enterobacterales isolates ( Fig. 1 A). Subtypes 
IV and VI annotated more rarely and almost exclusively to Enter- 
obacterales isolates. Subtypes III, V, and VII–XI were either absent 
or only of marginal presence in the NDARO annotations, suggest- 
ing the clinical relevance of these to be low (Supplementary Table 
S1). In summary, we consider only three subtypes to be of signifi- 
cant clinical relevance: I, II and, to a much lesser extent, IV. The 
presence of one or more aac(3) resistance genes was frequently 
found in Gram-negative clinical isolates; aac(3) genes were virtu- 
ally absent from Gram-positive isolates and mycobacteria. A de- 
tailed description of the database analysis including all of the rele- 
vant aac(3) resistance gene variants listed in the NDARO Reference 
Gene Catalog is provided as Supplementary material. 
Next we cloned the coding sequences of the clinically most 
prevalent (Supplementary Table S1) aac(3) amino acid sequences 
for each subtype into the Escherichia coli laboratory strain DH5 α. 
Promoter control allowed defined expression of individual resis- 
tance genes in an otherwise isogenic background and without in- 
terference by other phenotypic determinants, as previously de- 
scribed [5] . The aminoglycoside susceptibility patterns of the en- 
gineered aac(3) strains in broth microdilution assays revealed four 
distinct phenotypes across the five subtypes studied ( Fig. 1 B). Sub- 
type aac(3)-I conferred high-level resistance to gentamicin only. 
Subtypes II and VI conferred resistance to both gentamicin and 
tobramycin. Subtype aac(3)-III conferred resistance to gentamicin, 
tobramycin and neomycin, whereas subtype aac(3)-IV conferred 
resistance to gentamicin, tobramycin, neomycin, and apramycin. 
These four structurally distinct aminoglycosides appeared to pro- 
vide comprehensive and representative differentiation, since test- 
ing of additional aminoglycoside antibiotics did not result in fur- 
ther differentiation (data not shown). Susceptibility to amikacin, 
for instance, another important aminoglycoside in clinical use, was 
not affected by aac(3) resistance genes. 
Phylogenetic analysis of the amino acid sequences of the 
NDARO reference genes indicated genotypic clustering in accor- 
dance with the observed phenotypic resistance profiles ( Fig. 1 C). 
Subtype VI, for instance, which was found to share a susceptibil- 
ity profile with subtype II, also showed phylogenetic proximity to 
AAC(3)-II, prompting us to define a common clade for the two sub- 
types. Annotation of an aac(3) gene was always indicative of gen- 
tamicin resistance. Tobramycin is often used in the treatment of P. 
aeruginosa infections, which is in agreement with retained activ- 
ity against isolates that test positive for an aac(3) gene, because 
the large majority of these would be of subtype I, which does not 
appear to confer significant levels of resistance to tobramycin. In 
the case of Enterobacterales isolates, however, the annotation of an 
aac(3) gene is likely to be of subtype II, rendering the pathogen re- 
sistant to both gentamicin and tobramycin, while retaining amino- 
glycoside susceptibility to neomycin and apramycin. 
In summary, our results not only highlight careful differentia- 
tion of resistance gene variants as a critical prerequisite for indica- 
tive RGA, but also demonstrate a path forward towards in silico 
AST by combining systematic data mining with surrogate pheno- 
typic AST of distinct gene variants of clinical relevance. 
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Fig. 1. Clinical prevalence, phenotypic drug resistance, and genotypic diversity of the AAC(3) family of aminoglycoside acetyltransferase genes. (A) Summary of aac(3) resis- 
tance gene annotations in 239 772 human bacterial isolates deposited in the NCBI National Database of Antibiotic Resistant Organisms (NDARO). (B) Phenotypic susceptibility 
of engineered Escherichia coli strains to the four chemically distinct aminoglycoside antibiotics gentamicin (GEN), tobramycin (TOB), neomycin (NEO), and apramycin (APR). 
Each E. coli strain heterologously expresses an individual aac(3) gene under defined promoter control, in an otherwise isogenic background. Phenotypic susceptibility is 
expressed as a fold increase in the minimum inhibitory concentration (MIC) relative to the parental wild-type strain. (C) Unrooted phylogenetic tree of the amino acid se- 
quences of the 3- N -aminoglycoside acetyltransferase enzyme family AAC(3). Subtypes cloned and assessed in this study are highlighted in bold face. Phenotypic distinction 
associated with each clade is indicated by colour shading: GEN R , gentamicin resistance; TOB R , tobramycin resistance; NEO R , neomycin resistance; APR R , apramycin resistance. 
The NCBI accession numbers of the individual protein sequences are listed in Supplementary Table S3. 
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